



Impact on NHS workforce and resources

Resource impact

Published: 4 February 2019

www.nice.org.uk

This NICE guideline on <u>renal and ureteric stones</u>: <u>assessment and management</u> has been reviewed for its potential impact on the NHS workforce and resources. The guideline offers best practice advice on the assessment and management of renal and ureteric stones.

Recommendations likely to have an impact on resources

The recommendations that are most likely to have a substantial resource impact are:

- <u>Recommendation 1.5.3</u> For adults (16 years and over) offer shockwave lithotripsy (SWL) to treat ureteric stones less than 10 mm. Consider ureteroscopy if a previous course of shockwave lithotripsy has failed.
- Recommendation 1.5.5 Consider alpha blockers as adjunctive therapy for adults having SWL for ureteric stones less than 10 mm.

Context

Around 22,000 people in England had treatment for ureteric stones in 2016/17 (NHS Digital, Hospital Episodes Statistics).

Treatment for renal and ureteric stones is commissioned by clinical commissioning groups. Providers are NHS hospital trusts and private hospitals.

Resource impact

We estimate that if these recommendations are implemented, they would have the following impact:


- an increase in medical expulsive therapy for stones less than 10 mm
- an increase in SWL and a reduction in surgical interventions (ureteroscopy, or URS) for people with stones that are less than 10 mm who require a surgical intervention
- overall, cost savings for commissioners and efficiencies for providers.

The potential costs and savings to commissioners

The table and graph show the estimated budget impact for treating ureteric stones less than 10 mm over the first 5 years.

Recommendation	2018/19 (£000s)	2019/20 (£000s)	2020/21 (£000s)	2021/22 (£000s)	2022/23 (£000s)			
Current costs								
Medical expulsive therapy	17	17	17	17	17			
Ureteroscopy	11,408	11,408	11,408	11,408	11,408			
Shockwave lithotripsy	958	958	958	958	958			
Ureteroscopy following shockwave lithotripsy	922	922	922	922	922			
Total costs	13,305	13,305	13,305	13,305	13,305			

Recommendation	2018/19 (£000s)	2019/20 (£000s)	2020/21 (£000s)	2021/22 (£000s)	2022/23 (£000s)			
Future costs								
Medical expulsive therapy	20	38	55	73	87			
Ureteroscopy	11,140	9,801	8,461	7,122	6,050			
Shockwave lithotripsy	1,011	1,277	1,542	1,808	2,020			
Ureteroscopy following shockwave lithotripsy	991	1,337	1,682	2,028	2,305			
Total costs	13,163	12,452	11,741	11,030	10,461			
Savings - England	142	853	1,564	2,275	2,844			
Savings - per 100,000 population	0.3	1.5	2.8	4.1	5.1			



- Commissioners should be aware of the following:
 - the savings estimated (as shown above) are by undertaking less surgical activity (fewer URS) and increasing SWL
 - some lithotripsies are ineffective in removing the stone (clinical view is about 40%), so will require a subsequent ureteroscopy
 - if there are additional costs needed to establish networks of mobile or fixed lithotripters, it may take longer for savings to be realised.
- Providers should be aware of the following:
 - we estimate that, on average, providers would lose tariff income, due to commissioners paying less (see above)
 - there would be redistribution of income between providers from moving from surgery to shockwave therapy, because not all providers have lithotripters. In this area there may also be some additional costs associated with increased patient transport (as people require transport to hospital with lithotripters)
 - if providers do not have access to an on-site shockwave lithotripter, they should use local network arrangements to ensure people receive treatment within 48 hours
 - these changes are likely to free up acute bed capacity and therefore allow providers to manage acute bed capacity more efficiently.
- Commissioners and providers need to be aware of the recommendations within the
 Getting It Right First Time (GIRFT) Programme National Speciality Report on urology.
 The report highlights "The aim of urology networking will not be to concentrate all
 resources in a single location, but to encourage trusts to work together to balance
 workload, provide timely and appropriate care (especially emergency care) and ensure
 patients are treated by teams with greater experience in their condition."

Support to put the recommendations into practice

- NICE, NHS England and NHS Improvement support improvements in the treatment for renal and ureteric stones and more effective use of NHS resources.
- The Urology GIRFT Programme National Specialty Report on urology highlights the steps to improving treatment of urinary tract stones. See <u>recommendation 9</u> Improve the secondary care pathway for patients with urinary stones (page 32).
- The GIRFT programme is currently in discussions with providers to seek to develop urology area networks and identify examples of best practice, which may support implementation of these guidelines.

The guideline resource and implementation panel

The guideline resource and implementation panel reviews NICE guidelines that have a substantial impact on NHS resources. By 'substantial' we mean that:

- implementing a single guideline recommendation in England costs more than £1 million per year, or
- implementing the whole guideline in England costs more than £5 million per year.

Panel members are from NICE, NHS England, NHS Improvement, Health Education England and when appropriate Public Health England and Skills for Care. Topic experts are invited for discussions on specific topics.

The panel does not comment on or influence the guideline recommendations outside of NICE's usual consultation processes and timelines.